SNDL (SNDL) Competitors $1.78 -0.02 (-1.11%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends SNDL vs. CALT, DAWN, SPRY, PRAX, ANIP, AUPH, SYRE, ELVN, SNDX, and COLLShould you be buying SNDL stock or one of its competitors? The main competitors of SNDL include Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), ANI Pharmaceuticals (ANIP), Aurinia Pharmaceuticals (AUPH), Spyre Therapeutics (SYRE), Enliven Therapeutics (ELVN), Syndax Pharmaceuticals (SNDX), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. SNDL vs. Calliditas Therapeutics AB (publ) Day One Biopharmaceuticals ARS Pharmaceuticals Praxis Precision Medicines ANI Pharmaceuticals Aurinia Pharmaceuticals Spyre Therapeutics Enliven Therapeutics Syndax Pharmaceuticals Collegium Pharmaceutical SNDL (NASDAQ:SNDL) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking. Do analysts recommend SNDL or CALT? SNDL currently has a consensus target price of $3.25, suggesting a potential upside of 82.58%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, suggesting a potential downside of 1.88%. Given SNDL's stronger consensus rating and higher probable upside, analysts clearly believe SNDL is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SNDL 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation & earnings, SNDL or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than SNDL. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than SNDL, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSNDL$673.33MN/A-$127.91M-$0.31-5.74Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Is SNDL or CALT more profitable? SNDL has a net margin of -12.11% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. SNDL's return on equity of -8.27% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets SNDL-12.11% -8.27% -6.96% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Do institutionals & insiders have more ownership in SNDL or CALT? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor SNDL or CALT? SNDL received 114 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 72.31% of users gave SNDL an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformSNDLOutperform Votes14172.31% Underperform Votes5427.69% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Does the media refer more to SNDL or CALT? In the previous week, SNDL's average media sentiment score of 0.50 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that SNDL is being referred to more favorably in the media. Company Overall Sentiment SNDL Positive Calliditas Therapeutics AB (publ) Neutral Which has more volatility and risk, SNDL or CALT? SNDL has a beta of 3.17, indicating that its share price is 217% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. SummarySNDL beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks. Get SNDL News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDL vs. The Competition Export to ExcelMetricSNDLMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$1.22B$5.21B$9.14BDividend YieldN/AN/A5.13%4.02%P/E Ratio-5.7436.3789.3417.36Price / SalesN/A5.591,240.0477.11Price / CashN/A9.9643.7535.97Price / BookN/A2.045.314.79Net Income-$127.91M-$53.10M$122.54M$225.00M7 Day Performance-1.11%-1.14%0.59%2.62%1 Month Performance-1.11%-0.47%2.55%3.81%1 Year Performance23.61%-5.93%25.29%20.10% SNDL Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDLSNDL3.5169 of 5 stars$1.78-1.1%$3.25+82.6%+23.6%$0.00$673.33M-5.742,516Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180DAWNDay One Biopharmaceuticals1.9964 of 5 stars$11.67-1.1%$35.86+207.3%-9.9%$1.18BN/A-11.3360News CoverageSPRYARS Pharmaceuticals2.8686 of 5 stars$12.00+6.8%$24.50+104.2%+107.8%$1.17B$2.57M-23.5390PRAXPraxis Precision Medicines1.8854 of 5 stars$61.69-2.3%$146.33+137.2%+88.5%$1.15B$1.61M-5.99110ANIPANI Pharmaceuticals4.4737 of 5 stars$54.51-1.0%$77.71+42.6%+5.5%$1.15B$555.46M-99.11600Short Interest ↓Positive NewsGap DownAUPHAurinia Pharmaceuticals2.3116 of 5 stars$7.81-3.2%$10.00+28.0%+0.1%$1.12B$220.36M-52.06300Positive NewsSYRESpyre Therapeutics2.216 of 5 stars$21.55-4.1%$51.50+139.0%-14.5%$1.11B$890,000.00-2.88100ELVNEnliven Therapeutics2.2896 of 5 stars$22.21+2.2%$38.25+72.2%+50.0%$1.09BN/A-11.6950SNDXSyndax Pharmaceuticals3.7311 of 5 stars$12.66-3.4%$36.20+185.9%-36.8%$1.08B$16M-3.49110COLLCollegium Pharmaceutical4.2901 of 5 stars$33.47+1.7%$43.80+30.9%+1.1%$1.08B$599.25M14.43210 Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Alternatives Day One Biopharmaceuticals Alternatives ARS Pharmaceuticals Alternatives Praxis Precision Medicines Alternatives ANI Pharmaceuticals Alternatives Aurinia Pharmaceuticals Alternatives Spyre Therapeutics Alternatives Enliven Therapeutics Alternatives Syndax Pharmaceuticals Alternatives Collegium Pharmaceutical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNDL) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SNDL Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SNDL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
